Prelude Therapeutics INC 8-K Filing

Ticker: PRLD · Form: 8-K · Filed: Oct 24, 2024 · CIK: 1678660

Sentiment: neutral

Filing Stats: 509 words · 2 min read · ~2 pages · Grade level 12.7 · Accepted 2024-10-24 07:40:21

Key Financial Figures

Filing Documents

01 Other events

Item 8.01 Other events On October 24, 2024, Prelude Therapeutics Incorporated (the "Company") issued a press release announcing updated interim clinical data from its ongoing Phase 1 trial of PRT3789 and preclinical data from its precision degrader antibody conjugate program deploying a novel SMARCA2/4 dual degrader payload. The press release was issued simultaneously with the previously announced plenary session of the 36 th EORTC-NCI-AACR Symposium taking place in Barcelona, Spain. A copy of the press release is attached as Exhibit 99.1 to this report. In connection with the presentation of the clinical data, the Company has updated its corporate presentation. A copy of the updated corporate presentation is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release 99.2 Corporate presentation 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PRELUDE THERAPEUTICS INCORPORATED Date: October 24, 2024 By: /s/ Bryant Lim Bryant Lim Chief Legal Officer, Corporate Secretary, and Interim Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing